
Early MASH risk stratification, drug choice, and aligned coverage could improve outcomes, explained Zobair Younossi, MD.
Supplements and Featured Publications
over 24 years ago
Statin Pharmacology May Have Important Clinical Implicationsover 24 years ago
Role of hs-CRP in Cardiovascular Risk Predictionover 24 years ago
Changes in ATP III focus on diabetes and the metabolic syndromeover 24 years ago
Role of managed care in implementing NCEP-ATP III guidelinesover 24 years ago
Aggressive Lipid Reduction Provides Additional Clinical Benefit





